Limba
Romanian
Romanian
English|
Navicixizumab (Anti-DLL4), 1mg*5
11.102,70 RON
SKU
SKM_A2519_1mg*5
Navicixizumab (Anti-DLL4) is a bispecific monoclonal antibody targeting DLL4/VEGF. Navicixizumab can combine with Paclitaxel for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer. MW: 145.5 KD.
| Price | 9.330,00 RON (preturile sunt fara TVA) |
|---|---|
| Description |
Navicixizumab (Anti-DLL4) is a bispecific monoclonal antibody targeting DLL4/VEGF. Navicixizumab can combine with Paclitaxel for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer. MW: 145.5 KD. |
